Contact Wright Health

Let's move
the research forward.

Connect with us about peptide formulation, oncology research, development partnerships or investment.

Research & product partners

Build the next stage together.

We welcome conversations with formulation specialists, laboratories, clinical researchers and development partners aligned with our Skin & Tissue or Oncology programs.

Discuss a partnership

Investment inquiries

Capital tied to progress.

Wright Health is pursuing a proposed $8M staged financing for peptide product development and early oncology validation. Initial priorities include candidate selection, formulation or construct refinement, IP assessment and laboratory evidence.

Detailed allocations, study scopes and capital requirements will be reconciled with program budgets and quotations. Advancement depends on results and go/no-go decisions.

Request an investment discussion

Financing priorities / Intended outputs

What the first development stage is intended to produce.

A defined evidence package supports the next investment decision. Study scopes, acceptance criteria and costs must be finalized before execution.

SKIN & TISSUE

Distinct formulation plans

A topical cosmetic product profile and formulation dossier, alongside a separate oral BPC-157 development plan for deeper tissue repair/regeneration. Define exposure, safety, pre-clinical study requirements and manufacturing estimates for the therapeutic pathway.

ONCOLOGY

A pre-clinical evaluation package

A reviewed p53 RNA/DNA expression-vector and delivery strategy, defined protocols with controls and an initial in vitro data package. Appropriate in vivo studies follow when supported by the evidence, resources and ethical review.

INVESTMENT DECISION

A documented next-stage recommendation

Review the results against pre-agreed criteria, development risks, IP assessment, commercial options and a costed next-stage plan. Outcomes may support advancement, redesign or stopping a candidate.